Carotid artery disease: Current concepts on endothelial dysfunction and matrix remodeling

Current Drug Therapy

Volumn 4, Issue 3, 2009, Pages 202-213

  Romero, José Rafael ^a   Pikula, Aleksandra ^b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

Author keywords

ADMA; Carotid atherosclerosis; Endothelial dysfunction; Extracellular matrix; MMPs; NO

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ARGININE; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE DONOR; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN;

ADVANCED CANCER; ARTERY INTIMA PROLIFERATION; ARTERY PERMEABILITY; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE DISEASE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONNECTIVE TISSUE CELL; CONTRAST ENHANCEMENT; DIABETES MELLITUS; DISEASE COURSE; DISEASE MARKER; DRUG MECHANISM; DRUG TARGETING; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; EXTRACELLULAR MATRIX; HUMAN; HYPERLIPIDEMIA; IMAGING SYSTEM; MORTALITY; MUSCLE DISEASE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 73449088002     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488509789054974     Document Type: Review

References (153)

1. Sacco RL. Clinical practice. Extracranial carotid stenosis. N Engl J Med 2001; 345: 1113-18.
2. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363: 1491-02.
3. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273: 1421-28.
4. Mathiesen EB, Waterloo K, Joakimsen O, Bakke SJ, Jacobsen EA, Bonaa KH. Reduced neuropsychological test performance in asymptomatic carotid stenosis: The Tromso Study. Neurology 2004; 62: 695-01.
5. Oijen VM, de Jong, FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol 2007; 61: 403-10.
6. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
7. Lip GY, Blann AD. Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new 'vascular triad'. Ann Med 2004; 36: 119-25.
8. Galis, ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
9. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-38.
10. Assoian RK, Marcantonio EE. The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest 1996; 98: 2436-39.
11. Stary HC, Blankenhorn DH, Chandler AB, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 1992; 12: 120-34.
12. Shekhonin BV, Domogatsky SP, Idelson GL, Koteliansky VE, Rukosuev VS. Relative distribution of fibronectin and type I, III, IV, V collagens in normal and atherosclerotic intima of human arteries. Atherosclerosis 1987; 67: 9-16.
13. Piersol, George A. The ciculatory system. Textbook of Normal Histology including an account of the development of the tissues and the organs. 5th ed. Philadelphia: J.B. Lippincott Company 1897; Chapter VII.
14. Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol 1996; 8: 618-24.
15. Pearson JD. Normal endothelial cell function. Lupus 2000; 9: 183-88.
16. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
17. Hunt BJ, Jurd KM. Endothelial cell activation. A central pathophysiological process. BMJ 1998; 316: 1328-29.
18. Pober JS. Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium. Physiology and pathology. Am J Pathol 1988; 133: 426-33.
19. Panza JA, Quyyumi AA, Brush JE, Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.
20. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens 2001; 19: 415-20.
21. Monnink SH, van Haelst PL, van Boven AJ. Endothelial dysfunction in patients with coronary artery disease: a comparison of three frequently reported tests. J Investig Med 2002; 50: 19-4.
22. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106: 3073-78.
23. Rizzoni D, Porteri E, Guelfi D, et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001; 103: 1238-44.
24. Bolton CH, Downs LG, Victory JG, et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and proinflammatory cytokines. Nephrol Dial Transplant 2001; 16: 1189-97.
25. Raitakari M, Ilvonen T, Ahotupa M, et al. Weight reduction with very-low-caloric diet and endothelial function in overweight adults: role of plasma glucose. Arterioscler Thromb Vasc Biol 2004; 24: 124-28.
26. Virdis A, Ghiadoni L, Cardinal H, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-15.
27. Oida K, Ebata K, Kanehara H, Suzuki J, Miyamori I. Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. J Atheroscler Thromb 2003; 10: 93-8.
28. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
29. Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-31.
30. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
31. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
32. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 2004; 287: H782-790.
33. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide 2001; 5: 88-97.
34. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-5.
35. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-6.
36. Numaguchi K, Egashira K, Takemoto M, et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995; 26: 957-62.
37. Weidinger FF, McLenachan JM, Cybulsky MI, et al. Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation 1990; 81: 1667-79.
38. Kubo-Inoue M, Egashira K, Usui M, et al. Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery. Am J Physiol Heart Circ Physiol 2002; 282: H1478-84.
39. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr, Lerman A. "Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
40. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746-52.
41. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264: 10205-9.
42. Nijveldt RJ, Teerlink T, Van Der Hoven B, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 23-30.
43. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 996; 119: 1533-40.
44. Stuhlinger MC, Oka, RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003; 108: 933-8.
45. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
46. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92.
47. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-8.
48. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-3.
49. Sydow K, Schwedhelm E, Arakawa N, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57: 244-52.
50. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45: 1609-16.
51. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-6.
52. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: e53-9.
53. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-74.
54. Yoo JH., Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158: 425-30.
55. Wanby P, Teerlink T, Brudin L, et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006; 185: 271-7.
56. Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37: 2024-9.
57. Furuki K, Adachi H, Matsuoka H, et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis 2007; 191: 206-10.
58. Lundman P, Eriksson, MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111-6.
59. Furuki K, Adachi H, Enomoto M, et al. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertens Res 2008; 31: 1185-9.
60. Wanby P, Nilsson I, Brudin L, Nyhammar I, Gustafsson I, Carlsson M. Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. Acta Neurol Scand 2007; 115: 90-6.
61. Nanayakkara PW, Teerlink T, Stehouwer CD, et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005; 68: 2230-6.
62. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Grego F, Pauletto P. New markers of accelerated atherosclerosis in end-stage renal disease. J Nephrol 2003; 16: 11-20.
63. Zhang WR, Hou FF, Ning JP, et al. Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31: 621-8.
64. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-8.
65. Tousoulis D, Charakida M, Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 2005; 100: 347-53.
66. Tousoulis D, Antoniades C, Koumallos N, et al. Novel therapies targeting vascular endothelium. Endothelium 2006; 13: 411-21.
67. Hognestad A, Aukrust P, Wergeland R, et al. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 2004: 27: 199-203.
68. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211-6.
69. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 157-61.
70. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002; 15: 590-3.
71. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992; 20: 298-303.
72. Yagi S, Morita T, Katayama S. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004; 27: 129-35.
73. Russo G, Leopold JA, Loscalzo J. Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vascul Pharmacol 2002; 38: 259-69.
74. Schulz E, Tsilimingas N, Rinze R, et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 2002; 105: 1170-5.
75. Bode-Boger SM, Scalera F, Ignarro LJ. The l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 2007; 114: 295-306.
76. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93: 2135-41.
77. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80: 331-3.
78. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med 2000; 5: 11-9.
79. Tousoulis D, Davies G, Tentolouris C, Crake T, Toutouzas P. Coronary stenosis dilatation induced by L-arginine. Lancet 1997; 349: 1812-3.
80. Dhawan V, Handu SS, Nain CK, Ganguly NK. Chronic L-arginine supplementation improves endothelial cell vasoactive functions in hypercholesterolemic and atherosclerotic monkeys. Mol Cell Biochem 2005; 269: 1-11.
81. Cooke JP, Andon NA, Girerd XJ, Hirsch AT, Creager MA. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation 1991; 83: 1057-62.
82. Boger RH, Bode-Boger SM, Brandes RP, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997; 96: 1282-90.
83. Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager MA. Larginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990; 67: 1301-8.
84. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-6.
85. Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001; 8: 679-83.
86. Hu T, Chouinard M, Cox AL, et al. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem 2006; 281: 39831-8.
87. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
88. Hedin U, Roy J, Tran PK. Control of smooth muscle cell proliferation in vascular disease. Curr Opin Lipidol 2004; 15: 559-65.
89. Jackson CJ, Nguyen M. Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol 1997; 29: 1167-77.
90. Woessner JF., Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci 1994; 732: 11-21.
91. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006; 69: 614-24.
92. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
93. Partridge CA, Jeffrey JJ, Malik AB. A 96-kDa gelatinase induced by TNF-alpha contributes to increased microvascular endothelial permeability. Am J Physiol 1993; 265: L438-47.
94. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996; 157: 4159-65.
95. d'Ortho MP, Will H, Atkinson S, et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751-7.
96. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
97. Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002; 106: 3024-30.
98. Welgus HG, Senior RM, Parks WC, et al. Neutral proteinase expression by human mononuclear phagocytes: a prominent role of cellular differentiation. Matrix 1992; Suppl 1: 363-7.
99. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991; 277(Pt 1): 277-9.
100. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-9.
101. Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92: 1393-8.
102. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004; 110: 337-43.
103. Alvarez B, Ruiz C, Chacon P, Alvarez-Sabin J, Matas M. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 2004; 40: 469-75.
104. Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000; 31: 40-7.
105. Morgan AR, Rerkasem K, Gallagher PJ, et al. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke 2004; 35: 1310-5.
106. Bassiouny HS, Sakaguchi Y, Mikucki SA, et al. Juxtalumenal location of plaque necrosis and neoformation in symptomatic carotid stenosis. J Vasc Surg 1997; 26: 585-94.
107. Jacob T, Ascher E, Hingorani A, et al. Differential proteolytic activity and induction of apoptosis in fibrous versus atheromatous plaques in carotid atherosclerotic disease. J Vasc Surg 2001; 33: 614-20.
108. Higashikata T, Yamagishi M, Higashi T, et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method." Atherosclerosis 2006; 185: 165-72.
109. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503-9.
110. Levkau B, Kenagy RD, Karsan A, et al. Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells. Cell Death Differ 2002; 9: 1360-7.
111. Montero I, Orbe J, Varo N, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47: 1369-78.
112. Ferry G, Lonchampt M, Pennel L, de Nanteuil G, Canet E, Tucker GC. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett 1997; 402: 111-5.
113. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.
114. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78: 38-43.
115. Forough R, Koyama N, Hasenstab D, et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 1996; 79: 812-20.
116. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101: 1478-87.
117. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867-77.
118. Galis ZS, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 1998; 97: 2445-53.
119. King J, Zhao J, Clingan P, Morris D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 2003; 23: 639-45.
120. Miller KD, Saphner TJ, Waterhouse DM, et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 2004; 10: 1971-5.
121. Rizvi NA, Humphrey JS, Ness EA, et al. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004; 10: 1963-70.
122. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-33.
123. Kalela A, Laaksonen R, Lehtimaki T, et al. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol 2001; 88: 173-5, A176.
124. Cuccurullo C, Iezzi A, Fazia ML, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26: 2716-23.
125. Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003; 108: 1070-7.
126. Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53: 2662-8.
127. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
128. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-26.
129. Kizer JR, Dahlof B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45: 46-52.
130. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
131. Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 1995; 76: 8D-13D.
132. Cipollone F, Fazia M, Iezzi A, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482-8.
133. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004; 3: 913-25.
134. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 2005; 36: 2764-72.
135. Gronholdt ML, Nordestgaard BG, Wiebe BM, Wilhjelm JE, Sillesen H. Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. Circulation 1998; 97: 34-40.
136. Tegos TJ, Sohail M, Sabetai MM, et al. Echomorphologic and histopathologic characteristics of unstable carotid plaques. Am J Neuroradiol 2000; 21: 1937-44.
137. Polak JF, Shemanski L, O'Leary DH, et al. Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older. Cardiovascular Health Study. Radiology 1998; 208: 649-54.
138. Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation 2001; 103: 2171-5.
139. Tegos TJ, Kalomiris KJ, Sabetai MM, Kalodiki E, Nicolaides AN. Significance of sonographic tissue and surface characteristics of carotid plaques. Am J Neuroradiol 2001; 22: 1605-12.
140. Sabetai MM, Tegos TJ, Nicolaides AN, Dhanjil S, Pare GJ, Stevens JM. Reproducibility of computer-quantified carotid plaque echogenicity: can we overcome the subjectivity? Stroke 2000; 31: 2189-96.
141. Biasi GM, Froio A, Diethrich EB, et al. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. Circulation 2004; 110: 756-62.
142. Romero JR, Vasan RS, Beiser AS, et al. Association of carotid artery atherosclerosis with circulating biomarkers of extracellular matrix remodeling: the Framingham Offspring Study. J Stroke Cerebrovasc Dis 2008; 17: 412-7.
143. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
144. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-67.
145. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation 2003; 107: 455-60.
146. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003; 107: 2453-8.
147. Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000; 18: 321-5.
148. Okane K, Ibaraki M, Toyoshima H, et al. 18F-FDG accumulation in atherosclerosis: use of CT and MR co-registration of thoracic and carotid arteries. Eur J Nucl Med Mol Imaging 2006; 33: 589-94.
149. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48: 1818-24.
150. Rudd JH, Myers KS, Bansilal S, et al. Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007; 50: 892-6.
151. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-31.
152. Hartung D, Schafers M, Fujimoto S, et al. Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions. Eur J Nucl Med Mol Imaging 2007; 34(Suppl 1): S1-8.
153. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001; 7: 743-8.